Heatmap of fold-changes of metabolites. by Elena Heidenreich (6940475)

“…HL, i.e., 50 vs. 300 μmol photons m^-2 s^-1) for diploid (2N) and haploid (1N) <i>E</i>. …”

Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

“…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …”

Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study by Jon Jarløv Rasmussen (2993427)

“…</p><p>Methods</p><p>This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. …”

Cumulative distribution of EQ-5D-3L utilities decreasingly ordered before and after the onset of cutaneous leishmaniasis symptoms. by Janaína de Pina Carvalho (12152812)

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Figure S1 - Docosahexaenoic Acid Decreases Pro-Inflammatory Mediators in an <i>In Vitro</i> Murine Adipocyte Macrophage Co-Culture Model by Anna A. De Boer (510740)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

KOR-agonist (U50'488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. by Swantje C. Duncker (154707)

Relative Aggrecan mRNA expression levels, as measured by qPCR, in lentiviral-transduced control cells and 5 AggKD cell lines confirm decreased Aggrecan expression in the AggKD cell... by Juanita K. Hodax (6848540)

Influence of ghrelin treatment (0.5 μg/g BW, twice a day, intraperitoneal (ip.)) on survival, body weight and body temperature within 48 hours after cecal ligation and puncture (CL... by Daniel Siegl (717509)

The receiver operating characteristic curve (ROC) for using ucfDNA molecules with a size range of 130 to 160 bp within the DHSs to distinguish control subjects with hematuria from... by Meihui Chen (1670020)

Subjects:

Heatmap showing the end motifs of ucfDNA among different groups. by Meihui Chen (1670020)

Subjects:

ROC analysis for differentiating bladder cancer patients from controls using the ucfDNA concentration before and after normalization by creatinine concentration in those samples wi... by Meihui Chen (1670020)

Subjects:

Relationship of motif rankings in ucfDNA between WT and nuclease deficient mice. by Meihui Chen (1670020)

Subjects:

DNA concentrations of ucfDNA across WT, <i>Dnase1l3</i>^-/- and <i>Dnase1</i>^<i>-/-</i> mice with quantifiable ucfDNA using Qubit assay. by Meihui Chen (1670020)

Subjects:

Overview of the study design. by Meihui Chen (1670020)

Subjects:

The end density of ucfDNA across different tissue types. by Meihui Chen (1670020)

Subjects:

End density of the ucfDNA fragments within the DHSs. by Meihui Chen (1670020)

Subjects: